Published in Medical Letter on the CDC and FDA, July 12th, 2009
"The aim Of this study was to compare the pharmacokinetic properties and tolerability, and to determine bloequivalence, of a newly developed generic dispersible tablet formulation (test) and a branded capsule formulation (reference)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.